ClinicalTrials.gg
TerminatedNCT05215951MINOVAUpdated Oct 15, 2025Results posted

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC

A Phase 2 interventional study of osimertinib in Lung Cancer, sponsored by AstraZeneca. Terminated at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-15.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Why this study was terminated
Enrollment delay study timeline seriously.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing osimertinib in Lung Neoplasms — 10 open to participants now, 18 under way, 2 of them phase 3. osimertinib · Lung Neoplasms.

Enrollment
30th of 30
4 · median 52
Started
2022
with 1 other
Phase 2
16 of 30
5 open now
Registered
20th of 30
by date
Lead sponsor
10 of 30
AstraZeneca

Among the 30 studies testing osimertinib in Lung Neoplasms, this one is the 30th largest by enrollment, is one of 2 that started in 2022, is one of 16 in phase 2, and was the 20th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

10 of the 30 studies testing osimertinib in Lung Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing osimertinib in Lung Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, single-arm, multicenter, exploratory Phase II study sponsored by Astrazeneca Investment (China) Co., LTD. to evaluate the efficacy and safety of Osimertinib with Platinum plus Pemetrexed Chemotherapy, as First-line Treatment in Recurrent or Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients with Uncommon Epidermal Growth Factor Receptor Mutations (EGFRm).

Read the detailed description

Participants successfully enrolled into the study will receive 80mg osimertinib QD p.o. plus standard chemotherapy composed of cisplatin or carboplatin and pemetrexed i.v. on Day 1 of a 21 day cycle (every 3 weeks) for 4 to 6 cycles, followed by osimertinib 80 mg QD p.o. plus pemetrexed maintenance i.v. every 3 weeks until RECIST 1.1-defined radiological progression as judged by the investigator.

Tumour assessments will be performed as per RECISTv1.1 criteria, using computed tomography (CT)/magnetic resonance imaging (MRI). The baseline assessment is part of the screening procedures and should be performed before the start of study intervention.

safety will be assessed in the whole treatment period as well as 28 days after study drug termination for any reason.

03

Conditions studied

  • Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  2. Provision of signed and dated, written informed consent form prior to any mandatory study-specific procedures, sampling, and analyses.
  3. Male or female, at least 18 years of age.
  4. confirmed nonsquamous NSCLC.
  5. Newly diagnosed locally advanced (clinical stage IIIB, IIIC) or NSCLC (clinical stage IVA or IVB) or recurrent NSCLC (per Version 8 of the International Association for the Study of Lung Cancer [IASLC] Staging Manual in Thoracic Oncology), not amenable to curative surgery or radiotherapy.
  6. The tumour harbors at least 1 of the 4 uncommon EGFR mutations (G719X/L861Q/S768I/T790M), either alone or in combination, which not include other EGFR mutations including ex19del /L858R, assessed by one of ARMS, Super-ARMS or NGS analysis on the basis of tumour tissue or plasma testing from accredited laboratories approved by the Chinese regulatory authority.
  7. Participants must be considered suitable by investigator and about to receive standard of care which composed of pemetrexed plus carboplatin or cisplatin for 4 to 6 cycles followed by pemetrexed maintenance.
  8. Participants must have untreated advanced NSCLC not amenable to curative surgery or radiotherapy. Prior and neo-adjuvant therapies (chemotherapy, radiotherapy, immunotherapy, biologic therapy, agents), or definitive radiation/chemoradiation with or without regimens including immunotherapy, biologic therapy, investigational agents, are permitted as long as treatment was completed at least 6 months prior to the development of recurrent disease.
  9. Stable participants will be allowed.
  10. PS of 0 to 1 at screening with no deterioration in the previous 2 weeks.
  11. >12 weeks at Day 1.
  12. At least 1 lesion, not previously irradiated that can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes, which must have a short axis of ≥15 mm) with CT or MRI, and that is suitable for accurate repeated measurements. If only 1 exists, it is acceptable to be used (as a target lesion) as long as it has not been previously irradiated and as long as it has not been biopsied within 14 days of the baseline tumour assessment scans.
  13. Female must be using highly effective measures, must not be breast feeding, and must have a negative pregnancy test prior to first dose of study intervention or must have evidence of non- by fulfilling 1 of the following criteria at screening:

    • , defined as more than 50 years of age and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments
    • Women under 50 years old would be considered as postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and have luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the institution
    • Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation. Further information is available in Appendix E (Definition of Women of Childbearing Potential and Acceptable Contraceptive Methods).
  14. Male participants must be willing to use barrier contraception.

Exclusion criteria

Exclusion Criteria:

1.Spinal cord compression; symptomatic and unstable , except for those participants who have completed definitive therapy, are not on , and have a stable neurological status for at least 2 weeks after completion of the definitive therapy and steroids. Participants with asymptomatic brain metastases can be eligible for inclusion if in the opinion of the Investigator immediate definitive treatment is not indicated.

2 Past medical history of ILD, drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.

3 Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the Investigator's opinion makes it undesirable for the participant to participate in the trial or which would jeopardize compliance with the protocol, or active infection including any patients receiving treatment for infection but not limited to , and (HIV). Screening for chronic conditions is not required.

4.Any of the following cardiac criteria:

  • Mean resting interval (QTc) >470 msec, obtained from 3 (ECGs), using the screening clinic ECG machine-derived QTcF value;
  • Any abnormalities in rhythm, conduction, or morphology of resting ECG; eg, complete left bundle branch block, third-degree heart block, second-degree heart block;
  • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as electrolyte abnormalities including serum/plasma potassium*, magnesium* and calcium* below the lower limit of normal (LLN), heart failure, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes.

    5.Inadequate bone marrow or organ function reserve as demonstrated by any of the following laboratory values:

  • below the LLN *
  • count below the LLN*
  • \<90 g/L* *The use of granulocyte colony stimulating factor support, platelet transfusion and blood transfusions to meet these criteria is not permitted.
  • >2.5 x the (ULN) if no demonstrable liver or >5 x ULN in the presence of liver metastases
  • AST >2.5 x ULN if no demonstrable liver metastases or >5 x ULN in the presence of liver metastases
  • Total >1.5 x ULN if no liver metastases or >3 x ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases
  • \<60 mL/min calculated by Cockcroft and Gault equation (refer to Appendix G for appropriate calculation) 6.Any concurrent and/or other active that has required treatment within 2 years of first dose of study intervention (osimertinib, carboplatin and pemetrexed).

    7 Any unresolved toxicities from prior therapy (eg, chemotherapy) greater than Grade 1 at the time of starting study treatment, with the exception of alopecia and Grade 2 prior platinum-therapy related neuropathy. 8 nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib.

    9.Prior treatment with any systemic anti-cancer therapy for advanced NSCLC not amenable to curative surgery or radiation including chemotherapy, biologic therapy, immunotherapy, or any drug. Prior adjuvant and neo-adjuvant therapies (chemotherapy, radiotherapy, biologic therapy, investigational agents), or definitive radiation/chemoradiation with or without regimens including biologic therapies, investigational agents are permitted as long as treatment was completed at least 6 months prior to the development of recurrent disease.

    10.Prior treatment with an EGFR-TKI or immune-oncology (IO) therapy. 11.Major surgery within 4 weeks of the first dose of study intervention. Procedures such as placement of vascular access, via mediastinoscopy or biopsy via video assisted thoracoscopic surgery (VATS) are permitted.

    12.Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study intervention.

    13.Current use of (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP) 3A4 (at least 3 weeks prior) (Appendix F). All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on .

    14.Participation in another clinical study with an investigational product during the 4 weeks prior to Day 1. Participants in the follow-up period of an interventional study are permitted.

    15.Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and staff at the study site).

    16.Judgment by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.

    17.Previously enrolled in the present study. 18.Currently pregnant (confirmed with positive pregnancy test) or breast-feeding.

    19.History of to active or inactive of study intervention or drugs with a similar chemical structure or class to study intervention.

    20.In addition, the following conditions are considered criteria for exclusion:

  • Prior bone marrow transplant
  • Non-leukocyte depleted whole blood transfusion within 120 days of genetic sample collection.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Osimertinib plus standard chemotherapy

    single-arm

    Drug: osimertinib

Interventions

  • Dose Formulation: tablet; Dosage Level(s): osimertinib 80 mg QD for oral administration; Dosage formulation, dose reduction:40 mg QD for oral administration

    Also known as: AZD9291, Tagrisso

06

What researchers measure

Primary outcomes

  1. ORR

    ORR (objective response rate) defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) as their best overall response based on Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 as assessed by the investigator

    Time frame: Due to study early terminated, actual time frame is up to 24 weeks.

Secondary outcomes

  1. PFS

    PFS (Progression-free survival) will be defined as the time from first dose of study intervention until progression per RECIST 1.1 as assessed by the investigator or death due to any cause prior to PD (progressive disease).

    Time frame: Due to study early terminated, actual time frame is up to approximately 12 months.

  2. OS

    OS (Overall survival) is defined as the time from the first dose of treatment to the date of death, regardless of the actual cause of the subject's death. For participants who are still alive at the time of data analysis or who are lost to follow up, OS will be right-censored at the last recorded date that the participant is known to be alive prior to or at the data cut-off date for the analysis.

    Time frame: Due to study early terminated, actual time frame is up to approximately 13 months.

  3. DoR

    DoR (Duration of response) is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression. The end of response should coincide with the date of progression or death from any cause used for the PFS endpoint. The time of the initial response will be defined as the latest of the dates contributing toward the first visit response of PR or CR. If a participant does not progress following a response, then his/her duration of response will use the PFS censoring time as the end point for their DoR calculation.

    Time frame: Due to study early terminated, actual time frame is up to approximately 12 months.

  4. Depth of Response (Best Absolute Change in Target Lesion Tumour Size From Baseline)

    Depth of response (ie, tumour shrinkage / change in tumour size) by Investigator is defined as the relative change in the sum of the longest diameters of RECIST target lesions at the nadir in the absence of NLs (new lesions) or progression of NTLs (non-target lesions) when compared to baseline. The best absolute change in target lesion tumour size from baseline will be summarized using descriptive statistics. The best change in tumour size will include all assessments prior to progression or start of subsequent anti-cancer therapy.

    Time frame: Due to study early terminated, actual time frame is up to approximately 12 months.

  5. DCR

    DCR (disease control rate) is defined as the percentage of subjects who have a best overall response of CR or PR or SD (stable disease) by RECIST 1.1 as assessed by the Investigator. For participants with a best overall response of SD, a RECIST assessment of SD must have been observed at least 6 weeks following enrolment to be included in the numerator of the calculation for disease control rate. This is to enable sufficient follow-up to establish SD.

    Time frame: Due to study early terminated, actual time frame is up to approximately 12 months.

  6. TTF

    Time to treatment failure (TTF) or death is defined as defined as the time from first dose of study intervention (osimertinib) to earlier of the date of last study intervention administration or death due to any cause. Any participant not known to have permanently discontinued study intervention and not known to have died at the time of the analysis will be censored at the last known time on which the participant was known to be alive. Kaplan-Meier method will be used to estimate the median TTF and its 95% confidence interval.

    Time frame: Due to study early terminated, actual time frame is up to approximately 13 months.

  7. TFST

    Time to first subsequent therapy (TFST) or death is defined as the time from first dose of study intervention to the earlier of the date of anti-cancer therapy (except cisplatin or carboplatin or pemetrexed) start date following study intervention discontinuation or death due to any cause. Any participant not known to have had a subsequent therapy or not known to have died at the time of the analysis will be censored at the last known time to have not received subsequent therapy. Kaplan-Meier method will be used to estimate the median TFST and its 95% confidence interval.

    Time frame: Due to study early terminated, actual time frame is up to approximately 13 months.

  8. Depth of Response (Best Percentage Change in Target Lesion Tumour Size From Baseline)

    Depth of response (ie, tumour shrinkage / change in tumour size) by Investigator is defined as the relative change in the sum of the longest diameters of RECIST target lesions at the nadir in the absence of NLs or progression of NTLs when compared to baseline. Best percentage change in target lesion tumour size from baseline will be summarized using descriptive statistics. The best change in tumour size will include all assessments prior to progression or start of subsequent anti-cancer therapy.

    Time frame: Due to study early terminated, actual time frame is up to approximately 12 months.

07

Results

Posted Oct 15, 2025
Limitations and caveats
Enrollment to study D5161C00017 was terminated prior to completion of the study due to the delay in study enrollment. Due to the early termination of the study, only 4 participants (of the planned 35 participants) received study intervention and data collection for these participants was limited.

Participant flow

4 subjects enrolled in the study in total.

Participant flow — Overall Study
MilestoneOsimertinib Plus Standard Chemotherapy
Started4
Completed0
Not completed4

Outcome measures

PrimaryORR

ORR (objective response rate) defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) as their best overall response based on Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 as assessed by the investigator

Time frame:
Due to study early terminated, actual time frame is up to 24 weeks.
Reported as:
Number · Percentage of Patients
ORR
Percentage of PatientsOsimertinib Plus Standard Chemotherapy Single-arm
ORR75.0 (19.4 to 99.4)
SecondaryPFS

PFS (Progression-free survival) will be defined as the time from first dose of study intervention until progression per RECIST 1.1 as assessed by the investigator or death due to any cause prior to PD (progressive disease).

Time frame:
Due to study early terminated, actual time frame is up to approximately 12 months.
Reported as:
Median · Months
PFS
MonthsOsimertinib Plus Standard Chemotherapy Single-arm
PFSNA (3.29 to NA)
SecondaryOS

OS (Overall survival) is defined as the time from the first dose of treatment to the date of death, regardless of the actual cause of the subject's death. For participants who are still alive at the time of data analysis or who are lost to follow up, OS will be right-censored at the last recorded date that the participant is known to be alive prior to or at the data cut-off date for the analysis.

Time frame:
Due to study early terminated, actual time frame is up to approximately 13 months.
Reported as:
Median · Months
OS
MonthsOsimertinib Plus Standard Chemotherapy Single-arm
OSNA (3.94 to NA)
SecondaryDoR

DoR (Duration of response) is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression. The end of response should coincide with the date of progression or death from any cause used for the PFS endpoint. The time of the initial response will be defined as the latest of the dates contributing toward the first visit response of PR or CR. If a participant does not progress following a response, then his/her duration of response will use the PFS censoring time as the end point for their DoR calculation.

Time frame:
Due to study early terminated, actual time frame is up to approximately 12 months.
Reported as:
Median · Months
DoR
MonthsOsimertinib Plus Standard Chemotherapy Single-arm
DoRNA (NA to NA)
SecondaryDepth of Response (Best Absolute Change in Target Lesion Tumour Size From Baseline)

Depth of response (ie, tumour shrinkage / change in tumour size) by Investigator is defined as the relative change in the sum of the longest diameters of RECIST target lesions at the nadir in the absence of NLs (new lesions) or progression of NTLs (non-target lesions) when compared to baseline. The best absolute change in target lesion tumour size from baseline will be summarized using descriptive statistics. The best change in tumour size will include all assessments prior to progression or start of subsequent anti-cancer therapy.

Time frame:
Due to study early terminated, actual time frame is up to approximately 12 months.
Reported as:
Median · mm
Depth of Response (Best Absolute Change in Target Lesion Tumour Size From Baseline)
mmOsimertinib Plus Standard Chemotherapy Single-arm
Depth of Response (Best Absolute Change in Target Lesion Tumour Size From Baseline)47.50 (5.16 to 61.60)
SecondaryDCR

DCR (disease control rate) is defined as the percentage of subjects who have a best overall response of CR or PR or SD (stable disease) by RECIST 1.1 as assessed by the Investigator. For participants with a best overall response of SD, a RECIST assessment of SD must have been observed at least 6 weeks following enrolment to be included in the numerator of the calculation for disease control rate. This is to enable sufficient follow-up to establish SD.

Time frame:
Due to study early terminated, actual time frame is up to approximately 12 months.
Reported as:
Number · Percentage of patients
DCR
Percentage of patientsOsimertinib Plus Standard Chemotherapy Single-arm
DCR100 (39.8 to 100)
SecondaryTTF

Time to treatment failure (TTF) or death is defined as defined as the time from first dose of study intervention (osimertinib) to earlier of the date of last study intervention administration or death due to any cause. Any participant not known to have permanently discontinued study intervention and not known to have died at the time of the analysis will be censored at the last known time on which the participant was known to be alive. Kaplan-Meier method will be used to estimate the median TTF and its 95% confidence interval.

Time frame:
Due to study early terminated, actual time frame is up to approximately 13 months.
Reported as:
Median · Months
TTF
MonthsOsimertinib Plus Standard Chemotherapy Single-arm
TTFNA (3.29 to NA)
SecondaryTFST

Time to first subsequent therapy (TFST) or death is defined as the time from first dose of study intervention to the earlier of the date of anti-cancer therapy (except cisplatin or carboplatin or pemetrexed) start date following study intervention discontinuation or death due to any cause. Any participant not known to have had a subsequent therapy or not known to have died at the time of the analysis will be censored at the last known time to have not received subsequent therapy. Kaplan-Meier method will be used to estimate the median TFST and its 95% confidence interval.

Time frame:
Due to study early terminated, actual time frame is up to approximately 13 months.
Reported as:
Median · Months
TFST
MonthsOsimertinib Plus Standard Chemotherapy Single-arm
TFSTNA (3.94 to NA)
SecondaryDepth of Response (Best Percentage Change in Target Lesion Tumour Size From Baseline)

Depth of response (ie, tumour shrinkage / change in tumour size) by Investigator is defined as the relative change in the sum of the longest diameters of RECIST target lesions at the nadir in the absence of NLs or progression of NTLs when compared to baseline. Best percentage change in target lesion tumour size from baseline will be summarized using descriptive statistics. The best change in tumour size will include all assessments prior to progression or start of subsequent anti-cancer therapy.

Time frame:
Due to study early terminated, actual time frame is up to approximately 12 months.
Reported as:
Median · percentage change in tumour size
Depth of Response (Best Percentage Change in Target Lesion Tumour Size From Baseline)
percentage change in tumour sizeOsimertinib Plus Standard Chemotherapy Single-arm
Depth of Response (Best Percentage Change in Target Lesion Tumour Size From Baseline)53.61 (40.57 to 78.67)

Adverse events

Collected over From time of signature of informed consent form until 28 days after last dose of study intervention or until the end of study, whichever occurs earlier, up to 13.7 months when study terminated.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Osimertinib Plus Standard Chemotherapy1/4 (25%)0/4 (0%)4/4 (100%)
Most frequent other events
Showing 10 of 33
Most frequent other events
EventOsimertinib Plus Standard Chemotherapy
AnaemiaBlood and lymphatic system disorders3/4
White blood cell count decreasedBlood and lymphatic system disorders3/4
Alanine aminotransferase increasedHepatobiliary disorders2/4
Aspartate aminotransferase increasedHepatobiliary disorders2/4
Neutrophil count decreasedBlood and lymphatic system disorders2/4
Platelet count decreasedBlood and lymphatic system disorders2/4
Abdominal pain upperGastrointestinal disorders1/4
ArrhythmiaCardiac disorders1/4
AstheniaGeneral disorders1/4
Blood lactate dehydrogenase increasedHepatobiliary disorders1/4

Baseline characteristics

Age, Customized
Age, Customized(Participants)Osimertinib Plus Standard Chemotherapy Single-arm
18-1304
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Osimertinib Plus Standard Chemotherapy Single-arm
Female and male4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Osimertinib Plus Standard Chemotherapy Single-arm
Not collected4
08

Study locations

6 sites
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Harbin, 150049, China
  • Research Site
    Mianyang, 621000, China
  • Research Site
    Nanchong, 637000, China
  • Research Site
    Yibin, 644000, China
  • Research Site
    Zhengzhou, 450000, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Mar 2023, 13 months.

Results were first posted in Oct 2025, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2021
First posted
Jan 31, 2022
StartActual
Jan 19, 2022
Primary completionActual
Mar 9, 2023
CompletionActual
Mar 9, 2023
Results first posted
Oct 15, 2025
Last update
Oct 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05215951
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 31, 2022
Start date
Jan 19, 2022
Primary completion
Mar 9, 2023
Completion
Mar 9, 2023
Results posted
Oct 15, 2025
Last update
Oct 15, 2025

Study contacts

You Lu, Doctor
principal investigator · West China Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion